Further mechanism studies revealed that AMPK-mediated Nur77 suppression and subsequent mitochondrial function improvement played a key role in the therapeutic effects of FGF1ΔHBS on DCM (Figs. 6 and 7). This evidence concerns the gene PRKAA2 and familial dilated cardiomyopathy.